Milestone Pharmaceuticals Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Milestone Pharmaceuticals Inc. - overview
Established
2005
Location
-, QC, Canada
Primary Industry
Pharmaceuticals
About
Based in Quebec, Canada, and founded in 2005 by founder Philippe Douville, Milestone Pharmaceuticals, Inc. operates as a biopharmaceutical company providing the treatment of paroxysmal supraventricular tachycardia. As of 2024, the firm is listed on NASDAQ with ticker symbol MIST. In February 2024, Milestone Pharmaceuticals, Inc.
raised USD 30 million in a private placement, selling 16. 66 million shares at USD 1. 50 per share in the NASDAQ. The company has granted the underwriters a 30-day option to purchase up to 3,000,000 common shares at the public offering price.
Milestone Pharmaceuticals, Inc. developed an investigational product known as etripamil, which is a novel calcium channel blocker delivered as a nasal spray. The company’s product is designed for the acute at-home treatment of PSVT and AFib-RVR, allowing patients to manage their heart rhythm disturbances wherever they may be. In addition, the firm submitted a New Drug Application (NDA) to the U.
S. Food and Drug Administration (FDA) for etripamil, highlighting its potential to transform the standard of care for these conditions. The company plans to use the funding from February 2024 to use the net proceeds from the Offering to continue the development of etripamil in its lead indication of paroxysmal supraventricular tachycardia (PSVT) and its subsequent indication of atrial fibrillation with rapid ventricular rate (AFib-RVR), as well as for working capital and other general corporate purposes.
Current Investors
Domain Associates, GO Capital, BDC Capital
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Cardiology, Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.milestonepharma.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Milestone Pharmaceuticals Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Placement/Follow on | Completed | Milestone Pharmaceuticals Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.